HotSpot Therapeutics, a Cambridge, Mass.-based new biotechnology company targeting nature’s regulatory hotspots to discover and develop first-in-class medicines, completed a $45m Series A financing.
Backers included Atlas Venture and Sofinnova Partners.
Founded in 2017 by Jonathan Montagu, CEO, and Geraldine Harriman, PhD., Chief Scientific Officer, HotSpot Therapeutics is targeting nature’s regulatory mechanisms to create allosteric medicines. Its proprietary SpotFinder™ technology platform systematically identifies and targets “regulatory hotspots” – a family of allosteric sites used by nature to regulate protein function. Using bespoke chemistry approaches, HotSpot is developing a pipeline of first-in-class medicines for treatment of serious autoimmune and metabolic diseases.
The company has identified over 100 regulatory hotspots across a range of proteins and pathways. Its lead compounds include allosteric inhibitors that targets PKC-theta, for autoimmune diseases, and S6 kinase, an immunometabolic enzyme involved in the regulation of hepatic insulin sensitivity and mitochondrial function – an important new target for NASH and metabolic diseases.
Its Board of Directors include Bruce Booth, DPhil, Chairman and Partner at Atlas Venture, and Graziano Seghezzi, Managing Partner at Sofinnova Partners.